Latest Adherex Technologies (ADHXF) Headlines
Post# of 7
Posted On: 03/08/2014 4:58:09 PM
Latest Adherex Technologies (ADHXF) Headlines
OTC Signal Daily Stock Watch - Adherex Technologies Inc. (OTCQB: ADHXF)
WorldStockWire - Thu Sep 12, 2:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Adherex Announces Corporate Update
Marketwire - Thu Aug 15, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) announced today that David Lieberman has resigned from the Board of Directors. Rosty Raykov, CEO and a director of Adherex, will assume the role of Chairman of the Board of Directors. Robert Andrade has resigned as Chief Financial Officer and a director of the Company. Krysia Lynes, who has solid accounting background and has worked for Adherex since July 2010, will assume the role of Chief Financial Officer on an interim basis.
Adherex Reports Recent Developments and Second Quarter June 30, 2013 Financial Results
Marketwire - Fri Aug 09, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Reports Feedback from the FDA from End of Phase 2 Meeting
Marketwire - Thu May 23, 8:07PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinical study addressing the special ability of eniluracil/5-FU/leucovorin to meet the medical needs of these patients. However, the agency strongly recommended that Adherex consider other larger clinical trial design alternatives for the future development of eniluracil in MBC. In light of the Company's limited resources, Adherex is taking the Agency's recommendations into consideration as it reviews the feasibility of these and other clinical options.
Adherex Reports Recent Developments and First Quarter March 31, 2013 Financial Results
Marketwire - Mon May 13, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2012 Financial Results
Marketwire - Mon Apr 01, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), provided an update on recent progress with its clinical programs and reported financial results for the fiscal year ended December 31, 2012. All amounts are in U.S. dollars unless otherwise specified.
LifeSci Advisors Announces Investment Opinion on Adherex Technologies
Marketwire - Fri Mar 01, 12:37PM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Adherex Technologies Inc. (TSX: AHX) (OTCQB: ADHXF), a clinical-stage biotechnology company focused on the development of eniluracil (EU) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) to treat metastatic breast cancer. The drug is being compared to Xeloda(R) in a Phase II trial that completed enrollment at the end of 2012, with data expected in mid-2013. Preliminary results demonstrate that patients who had rapid disease progression on Xeloda and then crossed over to take EU/5-FU/LV experienced 89% clinical benefit and 33% tumor response. A small clinical trial with these patients may be an attractive path for rapid entry into the market.
Adherex Announces Completion of Patient Enrollment and Maintains TSX Listing Status
Marketwire - Sun Jan 06, 5:01PM CST
Adherex Technologies Inc. (TSX: AHX) (OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, is pleased to announce the following positive developments:
OTC Signal Daily Stock Watch - Adherex Technologies Inc. (OTCQB: ADHXF)
WorldStockWire - Thu Sep 12, 2:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Adherex Announces Corporate Update
Marketwire - Thu Aug 15, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF) announced today that David Lieberman has resigned from the Board of Directors. Rosty Raykov, CEO and a director of Adherex, will assume the role of Chairman of the Board of Directors. Robert Andrade has resigned as Chief Financial Officer and a director of the Company. Krysia Lynes, who has solid accounting background and has worked for Adherex since July 2010, will assume the role of Chief Financial Officer on an interim basis.
Adherex Reports Recent Developments and Second Quarter June 30, 2013 Financial Results
Marketwire - Fri Aug 09, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today reported its financial results and recent developments for the second quarter ended June 30, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Reports Feedback from the FDA from End of Phase 2 Meeting
Marketwire - Thu May 23, 8:07PM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), today announced that it has received feedback from the FDA at an End-of-Phase 2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to Metastatic Breast Cancer (MBC) patients who had rapid disease progression on capecitabine. Adherex proposed a small pivotal single arm clinical study addressing the special ability of eniluracil/5-FU/leucovorin to meet the medical needs of these patients. However, the agency strongly recommended that Adherex consider other larger clinical trial design alternatives for the future development of eniluracil in MBC. In light of the Company's limited resources, Adherex is taking the Agency's recommendations into consideration as it reviews the feasibility of these and other clinical options.
Adherex Reports Recent Developments and First Quarter March 31, 2013 Financial Results
Marketwire - Mon May 13, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today reported its financial results and recent developments for the first quarter ended March 31, 2013. All amounts are in U.S. dollars unless otherwise specified.
Adherex Provides Corporate Update and Fiscal Year Ended December 31, 2012 Financial Results
Marketwire - Mon Apr 01, 6:01AM CDT
Adherex Technologies Inc. (TSX: AHX)(OTCQB: ADHXF), provided an update on recent progress with its clinical programs and reported financial results for the fiscal year ended December 31, 2012. All amounts are in U.S. dollars unless otherwise specified.
LifeSci Advisors Announces Investment Opinion on Adherex Technologies
Marketwire - Fri Mar 01, 12:37PM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Adherex Technologies Inc. (TSX: AHX) (OTCQB: ADHXF), a clinical-stage biotechnology company focused on the development of eniluracil (EU) in combination with 5-fluorouracil (5-FU) and leucovorin (LV) to treat metastatic breast cancer. The drug is being compared to Xeloda(R) in a Phase II trial that completed enrollment at the end of 2012, with data expected in mid-2013. Preliminary results demonstrate that patients who had rapid disease progression on Xeloda and then crossed over to take EU/5-FU/LV experienced 89% clinical benefit and 33% tumor response. A small clinical trial with these patients may be an attractive path for rapid entry into the market.
Adherex Announces Completion of Patient Enrollment and Maintains TSX Listing Status
Marketwire - Sun Jan 06, 5:01PM CST
Adherex Technologies Inc. (TSX: AHX) (OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, is pleased to announce the following positive developments:
(0)
(0)